Rapamycin (Sirolimus)

Licensed by Pfizer 製品コードS1039 別名：AY 22989，NSC-2260804

分子量(MW)：914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

サイズ

価格(税別)

10mM/1mL In DMSO	JPY 52700
5mg	JPY 13600
25mg	JPY 46800
100mg	JPY 113200

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

具体的な在庫状況を確認してください。代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(217)

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

製品説明

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

ターゲット

mTOR ^[1]
(HEK293 cells)

~0.1 nM

体外試験

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. ^[1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. ^[2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. ^[3]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT-29	NEHyXHZEgXSxdH;4bYMhSXO\|YYm=	M3HpTVExKG6P	M3jRd\|czKGh?	NYe3fmdQTE2VTx?=	MXzQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm=	NEPXUWozPDlyMEi3Ny=>
HT-29	MnHKR5l1d3SxeHnjJGF{e2G7	NHH4NWIyOCCwTR?=	MlraO\|IhcA>?	NUDVTo9ZTE2VTx?=	M1P2RXBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?=	M2jCOVI1QTByOEez
HT-29	NI\YbHpEgXSxdH;4bYMhSXO\|YYm=	Mm\PNVAhdk1?	M2DlWVczKGh?	Ml3CSG1UVw>?	NEHh[nVRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?	MkLwNlQ6ODB6N{O=
PC3	NY\ONnRKU2mwYYPlJGF{e2G7	NXHKN2tDOTByIH7N	NH;3elIyKGh?	MUHEUXNQ	MVHQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?=	NUjmW5ZjOjF7N{i2PFM>
PC3	MUPLbY5ie2ViQYPzZZk>	M4jJbVExOCCwTR?=	NGT4TXEyKGh?	MljwSG1UVw>?	MUfEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?	MXmyNVk4QDZ6Mx?=
PC3	M{LGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXFT2JoOS53IN88US=>	MoHtNUBp	MXLEUXNQ	MUPJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN\|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1?	NWnoPWg6OjF7N{i2PFM>
HEK293	NVK2PY9mTnWwY4Tpc44hSXO\|YYm=	NYGzUXNpOTByIH7N	M{LNcFghcA>?	MnHkSG1UVw>?	NWDocllrUW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N	MVqyNVU{QTNyMR?=
BT-20	NGjRb2lMcW6jc3WgRZN{[Xl?	Mm\sNlAh\|ryP		M3LSbWROW09?	MoPlSI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25?	NYXROlBIOjF\|NUO1OVE>
U937	MXHBcpRq[mGldHXybYFtKEG\|c3H5	NUW1cXl5PTBizszN	MV[0PEBp	M{[3T2ROW09?	MljnTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy\|	NVjkeG1zOjFzNEKxNFY>
U937	M1znV2FvfGmkYXP0[ZJq[WxiQYPzZZk>	M2OycFUxKM7:TR?=	MYW0PEBp	NXvRZmZGTE2VTx?=	MmDmSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl\|NzDj[Yxtew>?	NY\NSlh[OjFzNEKxNFY>
U937	NWD0WotxSW62aXLhZ5RmemmjbDDBd5NigQ>?	MmOzOVAh\|ryP	Mk\XOFghcA>?	MXTEUXNQ	MUjEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=>	MVWyNVE1OjFyNh?=
MCF-7	MmTyRZV1d3CqYXf5JGF{e2G7	Mon2N\|Ahdk1?	NWPOZ5o5PCCq	M{jFfGROW09?	NUTx[3dNUW6mdXPld{BifXSxcHjh[5k>	NVfUXGYzOjByMkixN\|Q>
U87MG	NYDvcXlKU2mwYYPlJGF{e2G7	NY[4S21NOSEQvF2=	NEPacFA3KGh?	NIXVV4xFVVOR	NF;BOGxRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?=	Ml7zNVk5PDh2MES=
U87MG	Mm\nT4lv[XOnIFHzd4F6	NHLtdGMyKM7:TR?=	NHPZVWY3KGh?	NVzqUFNXTE2VTx?=	NWDYZmM3WG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44>	MXixPVg1QDRyNB?=
U87MG	NYnGSm1SU2mwYYPlJGF{e2G7	Mo\CNUDPxE1?	M33wUFYhcA>?	MXTEUXNQ	MWrEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?	NIK5[HcyQTh2OESwOC=>
U87MG	M3\LS2tqdmG\|ZTDBd5NigQ>?	NGnx[4UyKM7:TR?=	Mn;KOkBp	MkO3SG1UVw>?	MXfEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M\|Q3MSCyaH;zdIhwenmuYYTpc44>	NF;GS4MyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb	MW\BeZRweGijZ4mgRZN{[Xl?	NFHYTFIxNjJizszN	NVTSUYlwOjRiaB?=	MoPXSG1UVw>?	MVPJcoR2[2W\|IHH1eI9xcGGpeR?=	NWOwZ3RZOTh\|OUG5OFk>
COS7 cells expressing EGFP-LC3	NUTSTXNnSXW2b4DoZYd6KEG\|c3H5	NHn1b2UxNjJizszN	NHn3V40zPCCq	NY\UcmdGTE2VTx?=	MYnJcoR2[2W\|IHH1eI9xcGGpeR?=	MVuxPFM6OTl2OR?=
H4	M1joU2Z2dmO2aX;uJGF{e2G7	Mm[yNE4zKM7:TR?=	NGW4c3AzPCCq	NXrtV5Q6TE2VTx?=	NYTZVW5CUW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>?	NYLXO4o4OThyMkS1PFQ>
HeLa	MXHGeY5kfGmxbjDBd5NigQ>?	MYexNFAhdk1?	M2TLelM3KGh?	NVfCSXhWTE2VTx?=	NFP0dZZKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v	NWDNR4JyOTd3NkOzPFU>
HeLa	NH3TV41HfW6ldHnvckBCe3OjeR?=	MonaNVAxKG6P	MlOyN\|YhcA>?	MlLESG1UVw>?	MnLGTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v	MVKxO\|U3OzN6NR?=
HeLa	NVPmd4ZRTnWwY4Tpc44hSXO\|YYm=	MoO5NVAxKG6P	NVnuU2UzOzZiaB?=	MljUSG1UVw>?	Mmn2TY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u	NXjV[3NLOTd3NkOzPFU>
SYF	NYDxbmtwTnWwY4Tpc44hSXO\|YYm=	M3rSU\|ExOCCwTR?=	M3jRNFI1KGh?	MVHEUXNQ	NGqxUnRKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44>	NXjXSFRROTd3NkOzPFU>
SYF	NE\OdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWOxNFAhdk1?	MXuyOEBp	NEHpZ4tFVVOR	M3LlRWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDTXWYh[2WubIO=	M16zVVE4PTZ\|M{i1
HEK293T	M1zX[2FvfGm4aYLhcEBCe3OjeR?=	NH60XoIyKG6P	MoLPOEBl	NEDwe49FVVOR	MlHWTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2=	NVm0bml7OTd2OEW1NFE>
HEK293T	M1;qdWFvfGm4aYLhcEBCe3OjeR?=	M{TNO\|Ehdk1?	MkTCOEBl	Ml7iSG1UVw>?	MYrJcoR2[2W\|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?=	NU\4VIdkOTd2OEW1NFE>
PBMC	M{WwdGZ2dmO2aX;uJGF{e2G7	NEK2dY4yKG6P	NYTjfIgzOTRiZB?=	Mof3SG1UVw>?	NHzvZlBT\WS3Y3XzJGNEWjViZHXud4l1gQ>?	Mmj2NVc1QDV3MEG=
PBMC	MnvrSpVv[3Srb36gRZN{[Xl?	NIXSWJkyKG6P	NFLyVZoyPCCm	M2fvNGROW09?	MWLEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=>	MVmxO\|Q5PTVyMR?=
HEK293 cells	M4S4RmtqdmG\|ZTDBd5NigQ>?	M4eyOlUxKG6P	NIHlc5A1PSCvaX6=	NVi5dZVPTE2VTx?=	MYjJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O	M2W5dlE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc	NXLBfJhETnWwY4Tpc44hSXO\|YYm=	Mn;vNVAxKG6P	NW\RVI9{PCCq	MmqySG1UVw>?	MV7JcoR2[2W\|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2\|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=>	MYGxO\|EzQDJ4Mh?=
Human mixed lymphocyte	NWK4dlRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTXXZFtPSCwTR?=		MWfEUXNQ	NFHF[HNKSzVyPUGuOkBvVS5?	M{Lvd\|E3OTh3OE[1
Lewis rat lymph node cells	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi0OYc2KM7:TR?=		MV3EUXNQ	MnzQTWM2OD1{Lk[g{txO	Mn3MNVYyQDV6NkW=
cells from the thymus of normal BALB/c mice	NHqwOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYi0VG5tOTBibl2=	NV3CbHg6PzJiaB?=	NFOzZpJFVVOR	MnXRTY5pcWKrdIOgcJlueGixcILvcIln\XKjdHnvckApVEGIKTD3bZRpKEmFNUCgc4YhOyCwTR?=	MoH2NVAxOjF7NEi=
MRK-nu-1	MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7qdpc3UUN3ME2wMlg1PSCyTR?=	Ml22V2FPT0WU
OCUB-M	M4rHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3f0XmlEPTB;NT6yOEBxVQ>?	M2DEWnNCVkeHUh?=
SF539	NEf3U3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTPOZRIUUN3ME2xNU43KHCP	MXLTRW5ITVJ?
ES4	NVztfYlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWm2UHVnUUN3ME2yNU42KHCP	NFXvTY1USU6JRWK=
RL95-2	NET0eIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTFyNzDwUS=>	NVG5dYI4W0GQR1XS
LC-2-ad	M3nFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTR{MzDwUS=>	MXTTRW5ITVJ?
Daudi	M1TkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPKcI5KSzVyPUSzOEBxVQ>?	MnrZV2FPT0WU
NTERA-S-cl-D1	M2POTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnW3TWM2OD12NEOgdG0>	MUDTRW5ITVJ?
OS-RC-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHTfYQ2UUN3ME22OVIheE1?	M1PyOXNCVkeHUh?=
VA-ES-BJ	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\2R3NFUUN3ME23NlMheE1?	NVv1cJU{W0GQR1XS
GR-ST	M{Wxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{njOWlEPTB;OES2JJBO	MVTTRW5ITVJ?
SW872	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTh2NjDwUS=>	MVHTRW5ITVJ?
NOS-1	M2XrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\WTWM2OD16N{GgdG0>	NF3EPGxUSU6JRWK=
MC116	NYjnb2htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\GTWM2OD17OEWgdG0>	MU\TRW5ITVJ?
NCI-H1355	MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\CTWM2OD1zLkCxJI5O	M{LaUHNCVkeHUh?=
RPMI-8226	MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzCTWM2OD1zLkG5JI5O	MXHTRW5ITVJ?
TE-15	M4fWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTFwM{[gcm0>	NWnnbVNGW0GQR1XS
Ramos-2G6-4C10	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDiSY1KSzVyPUGuOFYhdk1?	MljkV2FPT0WU
KU812	Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3ESGJtUUN3ME2yMlAyKG6P	M2r6OXNCVkeHUh?=
EW-1	NIDTeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vmb2lEPTB;Mj6xO{BvVQ>?	NV7qOXJuW0GQR1XS
KS-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\5SGlEPTB;Mj60OUBvVQ>?	NWPwVmgzW0GQR1XS
SK-LMS-1	MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDWTWM2OD1{LkS5JI5O	NHy4[GxUSU6JRWK=
TGBC1TKB	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDSTWM2OD1{Lk[5JI5O	NXvXPVZZW0GQR1XS
TE-6	Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfVTWM2OD1{Lke3JI5O	MnXjV2FPT0WU
ETK-1	Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrD[XFiUUN3ME2yMlgzKG6P	M4TZb3NCVkeHUh?=
BE-13	NIe2dIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGr2UHRKSzVyPUKuPVkhdk1?	NWDiToROW0GQR1XS
A3-KAW	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFy3fHhKSzVyPUKuPVkhdk1?	NFnYbndUSU6JRWK=
TE-10	NWrKbYNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XaeWlEPTB;Mz6zJI5O	MWHTRW5ITVJ?
DOHH-2	MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jnUGlEPTB;Mz6zOUBvVQ>?	Ml6zV2FPT0WU
ES6	M3Ha[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7UdlVKSzVyPUOuOFMhdk1?	MXLTRW5ITVJ?
OPM-2	NVq3WJlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33CbGlEPTB;ND6xOUBvVQ>?	MoXDV2FPT0WU
SH-4	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkW1TWM2OD12LkO0JI5O	NFjvOHFUSU6JRWK=
NB13	Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDnTWM2OD12LkO2JI5O	MVnTRW5ITVJ?
HUTU-80	NFOyOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7ze3hKSzVyPUSuOFIhdk1?	NFTJSGhUSU6JRWK=
CCRF-CEM	M1;xcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTRwOUSgcm0>	MWHTRW5ITVJ?
TGBC24TKB	NHKycYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTVwNUGgcm0>	NH7jcY1USU6JRWK=
697	NFPTcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHOTWM2OD14LkK4JI5O	MXPTRW5ITVJ?
J-RT3-T3-5	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWX4UoNrUUN3ME22MlQ3KG6P	NITMU2tUSU6JRWK=
KALS-1	MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTZwNU[gcm0>	NIe5c3hUSU6JRWK=
no-10	MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPuVFJKSzVyPUeuNlkhdk1?	MV7TRW5ITVJ?
SK-NEP-1	Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXS0dHB6UUN3ME24Mlc6KG6P	MU\TRW5ITVJ?
L-540	MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDiTWM2OD1zMD60NkBvVQ>?	NH3selRUSU6JRWK=
JiyoyeP-2003	NYfOXllWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HSO2lEPTB;MUCuPVQhdk1?	M3SwZ3NCVkeHUh?=
HH	NGnSfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTxTWM2OD1zMT6zPUBvVQ>?	MVTTRW5ITVJ?
SR	M{DqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\QfpRKSzVyPUGxMlQ2KG6P	NI[zbGNUSU6JRWK=
QIMR-WIL	NFG1PFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrJRWM2UUN3ME2xNU45PSCwTR?=	NFPYOJlUSU6JRWK=
A4-Fuk	M4LabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlv6TWM2OD1zMz6xNkBvVQ>?	MYHTRW5ITVJ?
CESS	NHH0fIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTF\|LkGzJI5O	NF3pUYhUSU6JRWK=
KE-37	M4nMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPDTWM2OD1zNj6wO{BvVQ>?	MVrTRW5ITVJ?
SK-UT-1	MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jFS2lEPTB;MU[uPFEhdk1?	M2q2NHNCVkeHUh?=
SIG-M5	NUXXZ5l{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\oTWM2OD1zNz6yOUBvVQ>?	NVzsc3JJW0GQR1XS
HT	M1fWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXNd3RKSzVyPUG3MlYhdk1?	NW\R[WxTW0GQR1XS
DEL	NEm1PYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTF5Lkm5JI5O	NVfmOWt{W0GQR1XS
SK-PN-DW	NHXFUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDpTWM2OD1{MD6yN{BvVQ>?	M{XTWnNCVkeHUh?=
RPMI-8402	NWDVfGZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnznTWM2OD1{MT63O{BvVQ>?	NHnyRpFUSU6JRWK=
RPMI-6666	M1zmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWq2O\|RGUUN3ME2yOE41OiCwTR?=	Ml;KV2FPT0WU
NCI-H720	M2H4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\hSWxWUUN3ME2yOU41OSCwTR?=	MWXTRW5ITVJ?
EW-16	NHnmVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTJ4Lki3JI5O	MWPTRW5ITVJ?
BL-70	NIDUeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn[0TWM2OD1{OD6zPEBvVQ>?	NVS0[2dGW0GQR1XS
SF126	M2q0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXn0PHBSUUN3ME2zNE4{QCCwTR?=	M2[4WHNCVkeHUh?=
BC-1	NFez[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjyeFhMUUN3ME2zNU4zPiCwTR?=	MWLTRW5ITVJ?
MHH-PREB-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnG5TWM2OD1\|Mj60OEBvVQ>?	M1TpXXNCVkeHUh?=
A101D	M1nZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjkNJA4UUN3ME2zNk43OiCwTR?=	NEHKemFUSU6JRWK=
NMC-G1	M4\yNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI[2bmtKSzVyPUOzMlY4KG6P	MoW3V2FPT0WU
LB1047-RCC	NGfOcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTN2Lk[5JI5O	MkHrV2FPT0WU
EM-2	MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3BTWM2OD1\|OD61N{BvVQ>?	MYfTRW5ITVJ?
COLO-684	NXPpd2pMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHpTWM2OD1\|OT64JI5O	M{nuTHNCVkeHUh?=
Becker	NGP6VlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULZRlN[UUN3ME20NU4xPSCwTR?=	M2CyT3NCVkeHUh?=
BL-41	NUPiTFBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnPTWM2OD12Mz62OkBvVQ>?	MUTTRW5ITVJ?
MDA-MB-134-VI	NFX0bFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTR2LkCyJI5O	NFK5eolUSU6JRWK=
L-363	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTNOYpKSzVyPUS0Mlc{KG6P	MYPTRW5ITVJ?
ECC4	MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrNXmRKSzVyPUS0Mlc5KG6P	NVzpUmJuW0GQR1XS
A388	NG\3VpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYO1ZY9yUUN3ME20OE45OiCwTR?=	MXfTRW5ITVJ?
HEL	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELKSohKSzVyPUS5Mlc6KG6P	MUnTRW5ITVJ?
RKO	MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfoNol5UUN3ME21NE4zQSCwTR?=	NVXR[FdvW0GQR1XS
KINGS-1	NXPteWZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFX5d3hKSzVyPUWxMlU2KG6P	NEO4W2pUSU6JRWK=
EB-3	NXPhVGpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrhSVA{UUN3ME21Nk43PyCwTR?=	M{jDR3NCVkeHUh?=
ARH-77	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1X5WmlEPTB;NUKuPEBvVQ>?	M3XCUHNCVkeHUh?=
GCIY	NHy3V\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTV\|LkS2JI5O	M3vXPXNCVkeHUh?=
NCI-H1304	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PsWWlEPTB;NUeuNlIhdk1?	MkPJV2FPT0WU
KARPAS-299	NEPGPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoWyTWM2OD14MT64NkBvVQ>?	NInO[ZFUSU6JRWK=
IA-LM	MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVGyPHVzUUN3ME22PE4yOyCwTR?=	NHzkblVUSU6JRWK=
GI-1	NHnSO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWSz[pRLUUN3ME23NE4{QSCwTR?=	MWPTRW5ITVJ?
TE-11	M1e4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HId2lEPTB;N{euNVchdk1?	NEW2R3NUSU6JRWK=
LS-411N	NVzkOItPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTSWYtKSzVyPUe3MlU4KG6P	MWfTRW5ITVJ?
no-11	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjiXGdKSzVyPUizMlI1KG6P	Mom0V2FPT0WU
MV-4-11	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlH3TWM2OD16Mz63N{BvVQ>?	NWnsR4YzW0GQR1XS
BV-173	NFWzS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnLSGt5UUN3ME24N{46PyCwTR?=	Mn7PV2FPT0WU
CMK	MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn2wTWM2OD16ND6xOkBvVQ>?	NX;2Wog{W0GQR1XS
LC4-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4[5OWlEPTB;OE[uO\|Ihdk1?	NYK3d2hyW0GQR1XS
COR-L279	M3nyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDyb2UxUUN3ME24O{4zPSCwTR?=	NXqz[mV{W0GQR1XS
NCI-H209	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;mVWhKSzVyPUi3MlQyKG6P	M{TOTHNCVkeHUh?=
Raji	NF73fpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGm3[JNKSzVyPUi5MlczKG6P	MkHMV2FPT0WU
LB996-RCC	Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPaTWM2OD17Mz60N{BvVQ>?	MorRV2FPT0WU
NCI-H526	M17YWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHP5emlKSzVyPUmzMlU6KG6P	NHr3VYNUSU6JRWK=
KGN	Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTl4LkK5JI5O	NYr5eW44W0GQR1XS
MOLT-4	NULuZ\|V7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYH1W2xkUUN3ME25Ok44QSCwTR?=	MX3TRW5ITVJ?
PF-382	NEm3T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTl4Lke5JI5O	NU\TeFN2W0GQR1XS
BC-3	NEPHeIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTl7LkG4JI5O	Mn\WV2FPT0WU
KARPAS-422	M322Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnSzTWM2OD1zMEKuNFkhdk1?	NHHxXopUSU6JRWK=
SBC-1	NFvSTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TJS2lEPTB;MUC3Mlc2KG6P	MkfiV2FPT0WU
LC-1F	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HHdmlEPTB;MUC4MlA2KG6P	MnvTV2FPT0WU
GB-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHS[mh5UUN3ME2xNFkvODJibl2=	M1e1e3NCVkeHUh?=
SNB75	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnYTWM2OD1zMUmuOlkhdk1?	Ml3LV2FPT0WU
BB65-RCC	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIO3WZlKSzVyPUGxPU46OyCwTR?=	M3\mNXNCVkeHUh?=
NCI-N87	NXTpSIZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTF{MT65PEBvVQ>?	MmrBV2FPT0WU
IST-MEL1	NH\jO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDNTWM2OD1zMkKuN\|ghdk1?	NYfiPFFiW0GQR1XS
HOP-62	M3\aZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTF{Nj64PUBvVQ>?	NV\qUlVkW0GQR1XS
ACN	M1TCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTF2Nj63OUBvVQ>?	MnHoV2FPT0WU
DMS-114	NYDLOWxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTtXFRKSzVyPUG1NE43PyCwTR?=	NE\ueFFUSU6JRWK=
MLMA	NH7jS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\PSXNKSzVyPUG1PU45QCCwTR?=	MXjTRW5ITVJ?
HT-144	NX2wbIIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYi2boJqUUN3ME2xOlUvPDNibl2=	Mn7tV2FPT0WU
C2BBe1	M4KwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIP3OFNKSzVyPUG2O{44PiCwTR?=	NEfqPJFUSU6JRWK=
L-428	NIDMWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTF5Nz63JI5O	NGq5WmxUSU6JRWK=
DU-4475	M2XYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTF6Nz62PEBvVQ>?	M4rU[HNCVkeHUh?=
CP67-MEL	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\rWVJ3UUN3ME2xPVkvOzhibl2=	NFPEb\|ZUSU6JRWK=
MEG-01	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\vXGRZUUN3ME2yNFEvQTZibl2=	MkLvV2FPT0WU
IST-SL2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEX5epFKSzVyPUKwPE43OyCwTR?=	MkjpV2FPT0WU
ES8	NVS4SoZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoX6TWM2OD1{MkWuPVQhdk1?	NVzVc2NDW0GQR1XS
COLO-800	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknsTWM2OD1{M{WuNlghdk1?	NWnCSm9{W0GQR1XS
MFH-ino	NW\0d485T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTJ\|NT64OEBvVQ>?	MWrTRW5ITVJ?
OVCAR-4	NETkTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;TWVhvUUN3ME2yN\|cvOjRibl2=	NX\mbXVLW0GQR1XS
PSN1	M1nzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTJ2Mj63NUBvVQ>?	NX3RcoN6W0GQR1XS
EW-12	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTienVtUUN3ME2yOFMvOSCwTR?=	NIDxXVdUSU6JRWK=
HCC1599	NEnaRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTJ4MT60O{BvVQ>?	MXLTRW5ITVJ?
SJSA-1	NXHjTG9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Dk[2lEPTB;MkexMlQ3KG6P	MlLCV2FPT0WU
ST486	NHTCUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofaTWM2OD1{OU[uNVQhdk1?	NV;V[GRzW0GQR1XS
NOMO-1	MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTNyMD6yNUBvVQ>?	NGrONIxUSU6JRWK=
MN-60	M1jM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\WVHZKSzVyPUOwOU4{OiCwTR?=	NV3Ce4ZXW0GQR1XS
HCC1187	NIHQUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1z5SmlEPTB;M{C3MlI2KG6P	NVG1SnRzW0GQR1XS
SW982	NEDRNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPDTWM2OD1\|MUSuO\|Uhdk1?	M{TQenNCVkeHUh?=
LB647-SCLC	MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGf6ZphKSzVyPUOyPE44OSCwTR?=	NIr4R3VUSU6JRWK=
HC-1	M{jDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\V[FBDUUN3ME2zN\|UvPSCwTR?=	MoPlV2FPT0WU
EHEB	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTN\|Nz61NkBvVQ>?	MULTRW5ITVJ?
TUR	NVzze3RST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\nWGlEPTB;M{[zMlk2KG6P	NHrHT4NUSU6JRWK=
LU-139	NH7UTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXRZXpSUUN3ME2zO\|gvODJibl2=	NYjVSZFKW0GQR1XS
NB1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnv4TWM2OD1\|OESuOFUhdk1?	M1PCW3NCVkeHUh?=
BB30-HNC	M3vTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfxXJlKSzVyPUO4PE4{OiCwTR?=	NGWw[3FUSU6JRWK=
HAL-01	NV23[IZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTN6OT6yOkBvVQ>?	NG\jcI5USU6JRWK=
K5	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXtTWM2OD12MUGuN\|chdk1?	NGf1OmlUSU6JRWK=
MZ2-MEL	NHnCR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PFV2lEPTB;NEGzMlY1KG6P	NX\1OXpFW0GQR1XS
RXF393	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWX2R5B6UUN3ME20NVYvPDVibl2=	M{HXNnNCVkeHUh?=
NCI-H1648	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTRzNz61N{BvVQ>?	M1vTTHNCVkeHUh?=
TE-12	NUKxdphZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37OeGlEPTB;NEO0MlI3KG6P	MlTYV2FPT0WU
EoL-1-	M1iycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzYTWM2OD12M{euPVghdk1?	MVzTRW5ITVJ?
JAR	NX;KOINbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDFN5lKSzVyPUSzPE43OiCwTR?=	M2TXdnNCVkeHUh?=
DSH1	MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYn1WFZ{UUN3ME20OVgvQTFibl2=	MX;TRW5ITVJ?
NCI-H187	M2izeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;wUmlEPTB;NE[yMlgyKG6P	NVXOfWdFW0GQR1XS
HCE-4	NU\RU4NoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfZbpNKSzVyPUS3O{43PiCwTR?=	NXTnc2ZTW0GQR1XS
8-MG-BA	Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHmTWM2OD13OEGuOVIhdk1?	M4DtU3NCVkeHUh?=
KLE	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1S3OmlEPTB;NUi1MlIhdk1?	NHrZU4JUSU6JRWK=
KNS-42	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILHe5FKSzVyPUW4Ok45OSCwTR?=	MnfEV2FPT0WU
MSTO-211H	NYO3VphbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzqRmRKSzVyPU[wPU44PCCwTR?=	Ml\HV2FPT0WU
GDM-1	MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\YWmlEPTB;NkG0MlA6KG6P	NFfsVWRUSU6JRWK=
TE-1	M4nQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnezTWM2OD14NE[uNVIhdk1?	MV;TRW5ITVJ?
BT-474	M1HzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVezT\|lyUUN3ME22OFcvODZibl2=	MUHTRW5ITVJ?
KARPAS-45	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnaSHpKSzVyPU[0O{43KG6P	MXXTRW5ITVJ?
MOLT-16	MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTZ2Nz65N{BvVQ>?	MlvaV2FPT0WU
KURAMOCHI	NEjVcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTZ3Nz61NUBvVQ>?	MWnTRW5ITVJ?
K-562	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfHVopQUUN3ME22OlkvPTFibl2=	NWfEZlB4W0GQR1XS
EKVX	NGW1eo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml:zTWM2OD14N{KuO\|Ehdk1?	Mlu4V2FPT0WU
GAK	NUPWWnFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofyTWM2OD14N{WuN{BvVQ>?	NV3RcoZZW0GQR1XS
NCI-SNU-5	M1G5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHpTWM2OD14OUCuNFEhdk1?	MYPTRW5ITVJ?
NCI-H2126	NUPEWZBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWD5dI1WUUN3ME23NlYvQDdibl2=	MXHTRW5ITVJ?
CTV-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGP1[nZKSzVyPUe0OE46KG6P	M1fCeHNCVkeHUh?=
SW962	NYO3fpBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\3NmlEPTB;N{S4MlQ1KG6P	NIrodmNUSU6JRWK=
MONO-MAC-6	Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLnTWM2OD15NU[uPVMhdk1?	NHSwUZpUSU6JRWK=
NCI-H748	NEHQXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{H5bmlEPTB;N{W4Mlk6KG6P	MlvlV2FPT0WU
NCI-H524	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\ETWM2OD15OECuO\|Mhdk1?	NEnTbGZUSU6JRWK=
LS-123	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHiRlhKSzVyPUe5OU43QSCwTR?=	MlnlV2FPT0WU
NB7	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;2SmlKSzVyPUixOE4yPCCwTR?=	NGm1WmxUSU6JRWK=
LS-1034	NHnMOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrYTWM2OD16MkiuPVghdk1?	MV\TRW5ITVJ?
TE-5	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFP3UXFKSzVyPUi4N{42PiCwTR?=	MVvTRW5ITVJ?
A704	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{C2cGlEPTB;OEm5MlE2KG6P	M1POOXNCVkeHUh?=
TK10	M3fXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7LbY1NUUN3ME25NVYvODNibl2=	M3;obnNCVkeHUh?=
NCI-H345	M3L1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1e3XmlEPTB;OUSzMlIzKG6P	NGLSW3JUSU6JRWK=
CGTH-W-1	M{LRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTl2OD6xN{BvVQ>?	MWTTRW5ITVJ?
NCI-H510A	NEToS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnId5A3UUN3ME25PFUvOTJibl2=	NHvK[3hUSU6JRWK=
NCI-H1963	NInHdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTFwMEOyPVIh\|ryP	NEjTOHBUSU6JRWK=
SCC-3	NIPOdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zFcWlEPTB;MT6wN\|QyPCEQvF2=	MX;TRW5ITVJ?
EW-11	NI[4bnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XN[mlEPTB;MT6wPFc1OyEQvF2=	NWn0WXF6W0GQR1XS
CPC-N	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfDU5VKSzVyPUGuNFg5KM7:TR?=	NV\KV5dEW0GQR1XS
NCI-H1417	NHTBU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTFwMUKyOkDPxE1?	MWjTRW5ITVJ?
DG-75	M1LiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XjfGlEPTB;MT6xOlI5PSEQvF2=	M4TCXXNCVkeHUh?=
HD-MY-Z	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDYUphIUUN3ME2xMlE3PDF4IN88US=>	M3zGVnNCVkeHUh?=
ATN-1	NX;heFN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHnTWM2OD1zLkK2NlA6KM7:TR?=	MlLlV2FPT0WU
KM-H2	M1vRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7BTWM2OD1zLkK2OFA5KM7:TR?=	NGDFcWdUSU6JRWK=
NCI-H2081	NY\6T2pvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTFwMk[2N\|ch\|ryP	NX7wXVlVW0GQR1XS
HL-60	NHT6SoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTFwMk[5OVkh\|ryP	M{D6VHNCVkeHUh?=
DB	M1rXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDqeFQ1UUN3ME2xMlI4OjR{IN88US=>	NWLyVHFwW0GQR1XS
NCI-H1522	NXnJ[lhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPETWM2OD1zLkK4PFg4KM7:TR?=	MXjTRW5ITVJ?
AM-38	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTNR4NSUUN3ME2xMlMxPzJizszN	MULTRW5ITVJ?
NCI-H446	NWK1e3VRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLlTWM2OD1zLkOyNVIyKM7:TR?=	NYHoVol3W0GQR1XS
SU-DHL-1	NEj0UWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zZcmlEPTB;MT6zNlgxOSEQvF2=	M1vKZ3NCVkeHUh?=
NH-12	MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW[ySGxUUUN3ME2xMlM3Ozd2IN88US=>	NF7HbHlUSU6JRWK=
DMS-79	MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPGPXpKSzVyPUGuN\|Y5PjZizszN	NYXDfYdxW0GQR1XS
NCI-H716	NE\SXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfhTlZKSzVyPUGuN\|g6QDZizszN	NYT6[VlxW0GQR1XS
ML-2	M4[5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTFwNEG1Nlkh\|ryP	NISx[HpUSU6JRWK=
NB10	NY\vZpJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUX5NFZ3UUN3ME2xMlQ3PjN{IN88US=>	MoLoV2FPT0WU
ONS-76	NHTLUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTFwNUO1Olkh\|ryP	MV\TRW5ITVJ?
LOUCY	M2joRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTFwNUS2OVch\|ryP	NHjZNXJUSU6JRWK=
SCLC-21H	M3HYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzRTWM2OD1zLkW4OVgzKM7:TR?=	MWHTRW5ITVJ?
TGW	M1vjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTFwNkO5O\|Uh\|ryP	NVXzXppYW0GQR1XS
LXF-289	M3yzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTFwN{OyOlgh\|ryP	MnW5V2FPT0WU
BB49-HNC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTFwN{O1PFYh\|ryP	NHfwWWxUSU6JRWK=
NCI-H747	NG\Q[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWP3WoxxUUN3ME2xMlc2OzR4IN88US=>	NYrJbnRsW0GQR1XS
LU-165	M4LKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFGyS2tKSzVyPUGuPFQ6QDZizszN	NVHobpk1W0GQR1XS
OMC-1	M{DsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXSTWM2OD1zLkm1NFY3KM7:TR?=	M17YUXNCVkeHUh?=
RCC10RGB	NXWydlVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYCybJFCUUN3ME2xMlk2QDF5IN88US=>	MWLTRW5ITVJ?
SW684	NFnZSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PteWlEPTB;MT65OlA6QSEQvF2=	MX\TRW5ITVJ?
TE-8	MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7aTmpKSzVyPUKuNFU2PTlizszN	NFLETJZUSU6JRWK=
SK-N-DZ	M3PCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGX4bZRKSzVyPUKuNVMzPzRizszN	MWfTRW5ITVJ?
EVSA-T	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7XTlNKSzVyPUKuNVc{OTVizszN	NFOzOVFUSU6JRWK=
KASUMI-1	M4DpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrjTWM2OD1{LkG4PFE2KM7:TR?=	MXXTRW5ITVJ?
NKM-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTJwMkW0O\|Ih\|ryP	NIjHdWVUSU6JRWK=
CAL-148	M4jTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHj1UVRKSzVyPUKuN\|M3OTRizszN	MmDFV2FPT0WU
NCI-H64	M1zScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzmW4pFUUN3ME2yMlM1OjN{IN88US=>	NGLJXJZUSU6JRWK=
KNS-81-FD	MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rwd2lEPTB;Mj6zOlYzKM7:TR?=	Mn7CV2FPT0WU
KM12	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLZZ49KSzVyPUKuOFA5OzlizszN	NVHvS5dYW0GQR1XS
SW954	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTJwNEe3O\|kh\|ryP	NIT6XmNUSU6JRWK=
NCI-H1395	NGHGdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vrVGlEPTB;Mj61NlY1PSEQvF2=	MoTrV2FPT0WU
DJM-1	NGDZNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoflTWM2OD1{Lk[wOlMh\|ryP	MkHZV2FPT0WU
COLO-668	M1flS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILwcYxKSzVyPUKuPFI3QTVizszN	M2nG[nNCVkeHUh?=
NCI-H1436	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;mcmlEPTB;Mj64OVYyPSEQvF2=	MU\TRW5ITVJ?
LB2241-RCC	Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zhO2lEPTB;Mj64Olg{QSEQvF2=	NH;3U4FUSU6JRWK=
GT3TKB	NV\MTpR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2X0XmlEPTB;Mj64PVA2PSEQvF2=	MlH4V2FPT0WU
COLO-824	NWe5WGtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzFTWM2OD1{Lki5O\|Y5KM7:TR?=	MYjTRW5ITVJ?
ES1	M16yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1u3U2lEPTB;Mj64PVg4QSEQvF2=	MoPpV2FPT0WU
LB771-HNC	M1HCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF6xPYhKSzVyPUKuPVA6PDZizszN	M{nMdHNCVkeHUh?=
GI-ME-N	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fQUGlEPTB;Mz6wNFkxPCEQvF2=	MkTiV2FPT0WU
NALM-6	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfQcWVjUUN3ME2zMlAxQTN\|IN88US=>	MV;TRW5ITVJ?
LU-134-A	NXjYbVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmW3TWM2OD1\|LkC1OFI2KM7:TR?=	NYTQR3YzW0GQR1XS
DMS-153	MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HGT2lEPTB;Mz6wOVgzPCEQvF2=	M{jPeXNCVkeHUh?=
MZ1-PC	NHriO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULUPFQ6UUN3ME2zMlA6ODd6IN88US=>	NUfkeJAxW0GQR1XS
NCI-H1155	MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLSZYdKSzVyPUOuNVE3OSEQvF2=	MXrTRW5ITVJ?
CAS-1	NV3QSWhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTNwMUO3NFch\|ryP	Mn;XV2FPT0WU
D-502MG	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlG1TWM2OD1\|LkG0N\|kh\|ryP	M1rnRXNCVkeHUh?=
NCI-H2141	MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\PRWlEPTB;Mz6xO\|Q2OiEQvF2=	NGL3NXRUSU6JRWK=
NB6	NFLFNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH[1PFBKSzVyPUOuNVgzPTlizszN	NXr2OIl5W0GQR1XS
NCCIT	MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTiTWM2OD1\|LkKxPFA6KM7:TR?=	M163fHNCVkeHUh?=
NB69	M{G2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DK[mlEPTB;Mz6zNVg6OSEQvF2=	M1XPd3NCVkeHUh?=
JVM-2	M2XLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{OxOWlEPTB;Mz6zOlQ{OyEQvF2=	MYXTRW5ITVJ?
K052	NVzHemtPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7nTWM2OD1\|LkO3PVY5KM7:TR?=	MYfTRW5ITVJ?
HCC2157	M2rGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LtTWlEPTB;Mz61N\|IzQCEQvF2=	MX3TRW5ITVJ?
KMOE-2	Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHBVHdUUUN3ME2zMlU1OjR{IN88US=>	NF\aWnFUSU6JRWK=
SF268	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkD3TWM2OD1\|LkexOVU1KM7:TR?=	NGfWbZpUSU6JRWK=
CHP-126	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vo[mlEPTB;Mz63OlQ2QCEQvF2=	MoPPV2FPT0WU
CP66-MEL	NVHofWFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrUTWM2OD1\|Lke5NFk1KM7:TR?=	NFnr[oFUSU6JRWK=
NCI-H69	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\aUYlLUUN3ME20MlAyQTN4IN88US=>	M1;penNCVkeHUh?=
A253	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTRwMEKxNFEh\|ryP	MkfiV2FPT0WU
NB14	NGHkOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTRwMUC0O\|kh\|ryP	NFfnPHRUSU6JRWK=
NCI-H1694	NEnqWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1myeWlEPTB;ND6xN\|EyOiEQvF2=	MW\TRW5ITVJ?
NCI-H2196	MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XwS2lEPTB;ND6xO\|E3QSEQvF2=	MWfTRW5ITVJ?
TE-9	Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvLTWM2OD12LkG3OVgzKM7:TR?=	NYKzTlM2W0GQR1XS
D-283MED	NGjZXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYn0bndXUUN3ME20MlE5QDRizszN	NYC4NGlrW0GQR1XS
OCI-AML2	M{\tOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknjTWM2OD12LkG5OFg6KM7:TR?=	MmHiV2FPT0WU
D-263MG	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TtXWlEPTB;ND6yNlk3OSEQvF2=	NVfWTYhbW0GQR1XS
MPP-89	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\ZdWlEPTB;ND6yO\|MxPCEQvF2=	NV3pVGVOW0GQR1XS
LAMA-84	NGLMd\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFu2V3NKSzVyPUSuN\|A1OjFizszN	MYrTRW5ITVJ?
LB373-MEL-D	NIPTZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIm4[I5KSzVyPUSuN\|Y4QDlizszN	MV3TRW5ITVJ?
UACC-257	M2DPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NID5b4JKSzVyPUSuN\|k2OzRizszN	MVzTRW5ITVJ?
MC-CAR	MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTRwNEO5PUDPxE1?	MkXGV2FPT0WU
COLO-320-HSR	NVuzWmFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XZcmlEPTB;ND60OFQzPyEQvF2=	NFf1[o1USU6JRWK=
P30-OHK	NYX2eZN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLnTWM2OD12Lk[2OVgyKM7:TR?=	M1PsNnNCVkeHUh?=
UACC-812	NFHLc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTRwNkmxOlEh\|ryP	MnHhV2FPT0WU
CTB-1	NFXYZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4K0cmlEPTB;ND63NVU2PSEQvF2=	M4\M[3NCVkeHUh?=
ALL-PO	NFy5b2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M120N2lEPTB;ND64OFA4PyEQvF2=	MYfTRW5ITVJ?
SK-MEL-2	NX7nXFg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTRwOE[5OVUh\|ryP	MoOzV2FPT0WU
TC-YIK	NYXadVh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnBNFdsUUN3ME20Mlk4QTR{IN88US=>	MUTTRW5ITVJ?
NCI-H1882	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTVwMEKwNFEh\|ryP	MVjTRW5ITVJ?
MHH-CALL-2	MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PTSWlEPTB;NT6wOVA1OiEQvF2=	NHL2eZNUSU6JRWK=
U-87-MG	M{jyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPjSnp{UUN3ME21MlA6PDZ4IN88US=>	MVHTRW5ITVJ?
NCI-H1092	NYLVb41GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zjVGlEPTB;NT6yOlU2PSEQvF2=	Ml3sV2FPT0WU
TE-441-T	NIDEZ\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvhbZNIUUN3ME21MlI4QDJizszN	NEX5OXpUSU6JRWK=
SK-MEL-1	NF33ZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHacYNwUUN3ME21MlI6ODR2IN88US=>	M3fqd3NCVkeHUh?=
EW-22	NYrUfmJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4S3TGlEPTB;NT6yPVQ3PiEQvF2=	MnL2V2FPT0WU
MZ7-mel	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7WS4FKSzVyPUWuOFA3QTFizszN	MX7TRW5ITVJ?
LP-1	M1Tafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTVwNEGyPVEh\|ryP	NYj0WnUyW0GQR1XS
NCI-SNU-16	NWrwSW5pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonoTWM2OD13Lk[0NFc1KM7:TR?=	NITsUnRUSU6JRWK=
LU-65	M1;kVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTVwN{[zO\|Mh\|ryP	NEjpZnFUSU6JRWK=
CW-2	M{TtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PsNWlEPTB;NT64OVk2QSEQvF2=	M1LBRXNCVkeHUh?=
WSU-NHL	Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlO2TWM2OD13Lkm1NVc1KM7:TR?=	M2W0bHNCVkeHUh?=
IST-MES1	NXTvUI1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTVwOUW0OFMh\|ryP	MX\TRW5ITVJ?
U-266	M3i5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37LZmlEPTB;NT65PFIxOiEQvF2=	NGPmdFZUSU6JRWK=
TALL-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIH1TVZKSzVyPU[uNVQ3QDhizszN	NVXISYZpW0GQR1XS
Calu-6	NFTqXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TWZWlEPTB;Nj6xOVMyPiEQvF2=	MXLTRW5ITVJ?
MMAC-SF	MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTZwMUi1OVYh\|ryP	MnXaV2FPT0WU
NCI-H82	NVzC[4hTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHqdJdTUUN3ME22MlIxPDh7IN88US=>	NV;aSpRuW0GQR1XS
RS4-11	MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rwdGlEPTB;Nj6yOVg6PyEQvF2=	MVfTRW5ITVJ?
SNU-C2B	NXnhPGhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXQXmdxUUN3ME22MlQxQTZ7IN88US=>	NH;VUlJUSU6JRWK=
BOKU	NFvSd\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPUNGNKSzVyPU[uOFc2QTdizszN	Mlm2V2FPT0WU
C8166	NEDoOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTZwNUW5NVIh\|ryP	M3PpVnNCVkeHUh?=
D-247MG	NV75c\|JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTdwMESzOFch\|ryP	M1W2SnNCVkeHUh?=
EW-18	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1P6WGlEPTB;Nz6wO\|I6OiEQvF2=	MnLyV2FPT0WU
KG-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXjTWM2OD15Lk[yO\|M5KM7:TR?=	MkD2V2FPT0WU
REH	NYHRWYEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jHW2lEPTB;Nz62PFExQSEQvF2=	MmG4V2FPT0WU
U-698-M	NVixNHp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoH1TWM2OD15Lki0N\|E2KM7:TR?=	MonMV2FPT0WU
KP-N-RT-BM-1	M2S5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHMTotKSzVyPUeuPVMxOjlizszN	MVjTRW5ITVJ?
MS-1	MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37tWWlEPTB;Nz65OlA1OSEQvF2=	NU\2UVJCW0GQR1XS
SNU-C1	M{LZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7aTWM2OD15Lkm4NVkzKM7:TR?=	MlvvV2FPT0WU
SK-MM-2	M{HLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknnTWM2OD16LkK2NFY2KM7:TR?=	NGHy[VhUSU6JRWK=
LAN-6	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknQTWM2OD16LkOwNFAyKM7:TR?=	Ml20V2FPT0WU
NEC8	NGLzZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HNPGlEPTB;OD6zNFY6OSEQvF2=	M4nTWnNCVkeHUh?=
NCI-H1770	NGPNbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;FZZBKSzVyPUiuN\|gxODJizszN	M1L0ZnNCVkeHUh?=
D-336MG	M3jLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRThwNECxNVYh\|ryP	M1jjcXNCVkeHUh?=
COLO-829	NWDhRZRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moj3TWM2OD16LkS4PFc6KM7:TR?=	NWnleYxrW0GQR1XS
LS-513	MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRThwNUm1PVkh\|ryP	NIfCS4FUSU6JRWK=
YT	Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWqwOFF1UUN3ME24MlYzPDJ5IN88US=>	MVrTRW5ITVJ?
EW-24	M3HBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHS4d\|JKSzVyPUiuO\|Y2PCEQvF2=	Mn3oV2FPT0WU
IST-SL1	NVS5VodKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nnfWlEPTB;OD64OlU1OyEQvF2=	NEPaV\|VUSU6JRWK=
CA46	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfodY5KSzVyPUiuPVUxQThizszN	M4XH[nNCVkeHUh?=
NCI-H1838	NWj4dG5KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DLXGlEPTB;OD65PFYxOiEQvF2=	NWPxVZpQW0GQR1XS
NCI-H719	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;JZ2lEPTB;OT6yOVI4QSEQvF2=	M1fZRnNCVkeHUh?=
HCE-T	MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTlwM{C4OVEh\|ryP	M1nENnNCVkeHUh?=
A498	M1PWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPSTWM2OD17LkO2NVI1KM7:TR?=	MXjTRW5ITVJ?
LB831-BLC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17vRWlEPTB;OT63OlUzOSEQvF2=	MmnKV2FPT0WU
SKM-1	M1nvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHUTWM2OD17Lki1PVY{KM7:TR?=	MkjWV2FPT0WU
THP-1	NGXXNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTlwOU[5NVgh\|ryP	MlG3V2FPT0WU
SHP-77	NXf5SIEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkC5TWM2OD1zMD60NFch\|ryP	NVTqPJl6W0GQR1XS
EW-3	NVH2cFdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3WTWM2OD1zMD62Nlg6KM7:TR?=	NUHsOmNyW0GQR1XS
KY821	MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfsUmlKSzVyPUGwMlc3OyEQvF2=	NIXISFRUSU6JRWK=
NCI-SNU-1	M2XGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTFzLkCyNVch\|ryP	NWnYXpNFW0GQR1XS
HCC2218	M{e5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml21TWM2OD1zMT6zPVg3KM7:TR?=	MoDDV2FPT0WU
IM-9	MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW[2WGg2UUN3ME2xNU42OTB4IN88US=>	MoLJV2FPT0WU
NCI-H889	NUfWUoVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvmcGIzUUN3ME2xNU42OzF\|IN88US=>	NUC1dpNOW0GQR1XS
HDLM-2	MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;iO5ZOUUN3ME2xNk41OTV7IN88US=>	MV7TRW5ITVJ?
LB2518-MEL	M2HXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{m2VmlEPTB;MUKuOlgyPSEQvF2=	MonhV2FPT0WU
NCI-H23	NIHjeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzOeHJLUUN3ME2xN{4zPDJ3IN88US=>	MYrTRW5ITVJ?
NB17	NW\SdpVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTF\|LkS1O\|kh\|ryP	Mn7VV2FPT0WU
NCI-H322M	NWfNR2lYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvnOFZKSzVyPUG0MlQxPjhizszN	NYHSNnFjW0GQR1XS
SUP-T1	MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4iy[2lEPTB;MUSuOFE{KM7:TR?=	NHHlendUSU6JRWK=
ES3	MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTF3LkC3NFMh\|ryP	M3XBRnNCVkeHUh?=
ES5	NHLtTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDlR4ZKSzVyPUG1MlA4QDdizszN	M4S5dHNCVkeHUh?=
NCI-H1650	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoL0TWM2OD1zNT60PVc6KM7:TR?=	M1y2dXNCVkeHUh?=
NCI-H226	NWnPPHpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTF3Lki3Olgh\|ryP	NU\XWIYyW0GQR1XS
COR-L88	NFHlT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTF4LkOxOEDPxE1?	M3LUR3NCVkeHUh?=
SCC-15	Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2S1fmlEPTB;MU[uN\|g3QSEQvF2=	M3q2SXNCVkeHUh?=
GOTO	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYqybXd4UUN3ME2xOk41Pzl\|IN88US=>	NVvienJMW0GQR1XS
SIMA	MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4q3TmlEPTB;MU[uOFgxOiEQvF2=	M3HVU3NCVkeHUh?=
NCI-H1299	NVniNlZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXi2XoJ3UUN3ME2xO{4yPTlzIN88US=>	M4\LOnNCVkeHUh?=
NCI-H1581	NVHBW29PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7RSYN{UUN3ME2xO{41OjF7IN88US=>	NUWyb2RnW0GQR1XS
MHH-NB-11	M1vOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzUTWM2OD1zNz65Olg{KM7:TR?=	M3jJSXNCVkeHUh?=
MFM-223	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTLTWM2OD1zOD6wOVM5KM7:TR?=	NXSxbXFzW0GQR1XS
ES7	NVK5fZJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPBd\|dKSzVyPUG4MlU1OzFizszN	NVTOe4ZJW0GQR1XS
JVM-3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLLTWM2OD1zOD63NVch\|ryP	NX3ONIJYW0GQR1XS
RL	NIHK[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3wO4FKSzVyPUKwMlM5QCEQvF2=	MkPXV2FPT0WU
EC-GI-10	NFnoVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\kW2lEPTB;MkGuNlA1OSEQvF2=	MWDTRW5ITVJ?
LNCaP-Clone-FGC	NVnqe2pKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrrSXBsUUN3ME2yNU43PzZ6IN88US=>	NIT4UmJUSU6JRWK=
IMR-5	NYn1dVdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjUW\|VKSzVyPUKxMlg1QTRizszN	MmO1V2FPT0WU
KP-N-YS	MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn2wTWM2OD1{MT64O\|Uh\|ryP	Mn\NV2FPT0WU
Mo-T	NGPYWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTJ{LkKxPFUh\|ryP	MnixV2FPT0WU
NCI-H128	NHzzcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rhNmlEPTB;MkOuOVg2OyEQvF2=	MYTTRW5ITVJ?
RH-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY[0UHRzUUN3ME2yN{44QDZ4IN88US=>	NUXEbWtpW0GQR1XS
NCI-H2171	NFXWWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTJ2LkK0PFUh\|ryP	M{XNVHNCVkeHUh?=
RPMI-8866	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTJ4Lke0NkDPxE1?	MoPHV2FPT0WU
SK-N-FI	MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TZZWlEPTB;MkeuN\|gyOSEQvF2=	MX;TRW5ITVJ?
LOXIMVI	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXHTWM2OD1{Nz64NFUyKM7:TR?=	Mof2V2FPT0WU
P31-FUJ	MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\mOWlEPTB;M{GuOVM4PCEQvF2=	MlLFV2FPT0WU
KMS-12-PE	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfzcm5KSzVyPUS5MlU{ODJizszN	NEnZcGlUSU6JRWK=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	p-mTOR(S2448)/mTOR; PubMed: 23991038 PLoS One MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.	23991038
Growth inhibition assay	Cell proliferation; PubMed: 30393233 Biosci Rep (A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.	30393233
Histomorphology	Haematoxylin & Eosin; PubMed: 28418837 Oncotarget Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.	28418837
Immunofluorescence	NeuN; PubMed: 28418837 Oncotarget Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown. p62/Beclin; PubMed: 28819214 Sci Rep (C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody.	28418837 28819214
ELISA	Type III collagen/Fibronectin; PubMed: 23364979 Yonsei Med J (A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.	23364979

体内試験

Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. ^[4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. ^[5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. ^[6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. ^[7]

お薦めの試験操作（参考用のみ）

キナーゼ試験： ^[1]	+ 展開 Immunoblotting for the mTOR kinase assay: HEK293 cells are plated at 2-2.5×10⁵ cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
細胞試験： ^[3]	+ 展開細胞株： U87-MG, T98G, and U373-MG 濃度： Dissolved in DMSO, final concentrations ~25 μM 反応時間： 72 hours 実験の流れ： Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope. (参考用のみ)
動物試験： ^[7]	+ 展開動物モデル： Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells 製剤： Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O) 投薬量： ~4 mg/kg/day 投与方法： Injection i.p. (参考用のみ)

参考

+ 展開

溶解度 (25°C)

体外	DMSO	20 mg/mL (21.87 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 混合させたのち直ちに使用することを推奨します。	5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Rapamycin (Sirolimus) SDFをダウンロードする

分子量	914.18
化学式	C₅₁H₇₉NO₁₃
CAS No.	53123-88-9
保管	3年 -20°C 粉
保管	2年 -80°C in solvent
別名	AY 22989，NSC-2260804

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03866681	Not yet recruiting	Paroxysmal Nocturnal Hemoglobinuria	Peking Union Medical College Hospital	April 1 2019	Phase 4
NCT03454724	Not yet recruiting	Coronary Artery Disease	Meril Life Sciences Pvt. Ltd.	April 1 2019	Not Applicable
NCT03877809	Not yet recruiting	Beta-Thalassemia	Rare Partners srl Impresa Sociale\|Università degli Studi di Ferrara	April 1 2019	Phase 2
NCT03866681	Not yet recruiting	Paroxysmal Nocturnal Hemoglobinuria	Peking Union Medical College Hospital	April 1 2019	Phase 4
NCT03454724	Not yet recruiting	Coronary Artery Disease	Meril Life Sciences Pvt. Ltd.	April 1 2019	Not Applicable
NCT03877809	Not yet recruiting	Beta-Thalassemia	Rare Partners srl Impresa Sociale\|Università degli Studi di Ferrara	April 1 2019	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

mTORシグナル伝達経路

mTOR Inhibitors with Unique Features

Pan mTOR inhibitor

KU-0063794 : mTORC1 and mTORC2, IC50=~10 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

相関mTOR製品

MHY1485

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021)

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C, BML-275)

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

研究分野別

製品類型

Rapamycin (Sirolimus)

文献中Selleckの製品使用例(217)

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Rapamycin (Sirolimus) SDFをダウンロードする

便利ツール

モル濃度計算器

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技術サポート

mTORシグナル伝達経路

mTOR Inhibitors with Unique Features

相関mTOR製品